The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Reporting immunoglobulin gene analysis in CLL: updates to the ERIC guidelines
Anastasia Chatzidimitriou, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses updates to the European Research Initiative on CLL (ERIC) recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia (CLL). This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, these recommendations for robust immunogenetic analysis exist thanks to the dedicated efforts by ERIC covering all the phases from the pre-analytical and analytical to the post-analytical pertaining to the analysis, interpretation, and reporting of the findings. This is what we’re going to discuss during the workshop in Barcelona. Lately, in 2022, we have updated these recommendations regarding different parts of the analytical procedure...
So, these recommendations for robust immunogenetic analysis exist thanks to the dedicated efforts by ERIC covering all the phases from the pre-analytical and analytical to the post-analytical pertaining to the analysis, interpretation, and reporting of the findings. This is what we’re going to discuss during the workshop in Barcelona. Lately, in 2022, we have updated these recommendations regarding different parts of the analytical procedure. For example, the methodology, we recommend that the primers and the sequencing method and the bioinformatics tools that have been used for somatic hypermutation status assessment, they are all reported in the lab report. Also regarding factionality, for example, the somatic hypermutation status should be determined only for the productive rearrangements, and if the rearrangement is unproductive, then we should mention the reasons for that. Also another update is that currently there is another feature in the IMGT analysis tool, we can define the subsets, especially subsets 2 and 8, the two aggressive subsets, through this tool.
Read more...
Disclosures
Unrestricted grants from Novartis, Janssen.
